Create a free QxMD account to take advantage of the features offered by Read like saving your papers and creating collections.

Get Started

COMPARATIVE STUDY

LETTER

Comment and reply on: A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective

Jorge Arellano, Claudia Leteneux

Journal of Medical Economics 2008, 11 (2): 363-66; author reply 366-70

No abstract text is available yet for this article.

Full Text Links

Find Full Text Links for this Article

You are not logged in. Sign Up or Log In to join the discussion.

A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer. Mark J C Nuijten, Javier de Castro Carpeño, Christos Chouaid, Alain Vergnenègre, Francesco Grossi, Helge Bischoff, David Heigener, Stefan Walzer Lung Cancer: Journal of the International Association for the Study of Lung Cancer 2012, 76 (3): 465-71

Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective. Stephen Doral Stefani, Mario Giorgio Saggia, Eduardo Augustus Vicino dos Santos Journal of Medical Economics 2008, 11 (3): 383-96

Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting. Eric Nadler, Michael Forsyth, Sacha Satram-Hoang, Carolina Reyes Journal of Thoracic Oncology 2012, 7 (1): 212-8

Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer. Josh J Carlson, William B Wong, David L Veenstra, Carolina Reyes Journal of Medical Economics 2011, 14 (2): 159-66

Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population. Yumi Asukai, Amparo Valladares, Carlos Camps, Eifiona Wood, Kaisa Taipale, Jorge Arellano, Alejo Cassinello, José Antonio Sacristán, Tatiana Dilla BMC Cancer 2010, 10: 26

Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom. G Lewis, M Peake, R Aultman, M Gyldmark, L Morlotti, J Creeden, M de la Orden Journal of International Medical Research 2010, 38 (1): 9-21

Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysis. Ian Cromwell, Kimberly van der Hoek, Barbara Melosky, Stuart Peacock Journal of Thoracic Oncology 2011, 6 (12): 2097-103

Editorial: Comparative efficacy and cost associated with new agents in the treatment of non-small cell lung cancer (NSCLC). Elvira Mueller Lung Cancer: Journal of the International Association for the Study of Lung Cancer 2010, 69 Suppl 1: S1-3

3rd line Erlotinib for lung cancer in Asia may be as cost-effective as in the Western world. Ching-Chan Lin, Te-Chun Hsia, Chun-Ru Chien Lung Cancer: Journal of the International Association for the Study of Lung Cancer 2012, 76 (3): 499-500

Make the most of Read.
Download the mobile app.

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

Read